Search Results for: -trf7pw.html

ACTUATE THERAPEUTICS’ CONGRATULATES DR. PATRICIA LORUSSO ON BEING NAMED AACR PRESIDENT-ELECT

CHICAGO, IL and FORT WORTH, TX, March 23, 2023 – Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board has been elected as President-Elect of the American Association of Cancer Research for […]

ACTUATE THERAPEUTICS’ CONGRATULATES DR. PATRICIA LORUSSO ON BEING NAMED AACR PRESIDENT-ELECT Read More »

DRS. ROGER B. COHEN, LEE M. ELLIS AND JOHN L. MARSHALL JOIN ACTUATE THERAPEUTICS’ SCIENTIFIC ADVISORY BOARD

CHICAGO, IL and FORT WORTH, TX, October 18, 2022 – Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced the addition of eminent cancer research leaders Roger B. Cohen, MD, Lee M. Ellis, MD, and John L. Marshall, MD to their Scientific Advisory Board.  Dr. Roger

DRS. ROGER B. COHEN, LEE M. ELLIS AND JOHN L. MARSHALL JOIN ACTUATE THERAPEUTICS’ SCIENTIFIC ADVISORY BOARD Read More »